載入...
HSP90 inhibitor, AUY922, debilitates intrinsic and acquired lapatinib-resistant HER2-positive gastric cancer cells
Human epidermal growth factor receptor 2 (HER2) inhibitors, such as trastuzumab and lapatinib are used to treat HER2-positive breast and gastric cancers. However, as with other targeted therapies, intrinsic or acquired resistance to HER2 inhibitors presents unresolved therapeutic problems for HER2-p...
Na minha lista:
| 發表在: | BMB Rep |
|---|---|
| Main Authors: | , , , , , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Korean Society for Biochemistry and Molecular Biology
2018
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6330940/ https://ncbi.nlm.nih.gov/pubmed/30591093 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5483/BMBRep.2018.51.12.259 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|